KR20200046061A - 스피로사이클 화합물 및 이를 제조하고 사용하는 방법 - Google Patents

스피로사이클 화합물 및 이를 제조하고 사용하는 방법 Download PDF

Info

Publication number
KR20200046061A
KR20200046061A KR1020207008312A KR20207008312A KR20200046061A KR 20200046061 A KR20200046061 A KR 20200046061A KR 1020207008312 A KR1020207008312 A KR 1020207008312A KR 20207008312 A KR20207008312 A KR 20207008312A KR 20200046061 A KR20200046061 A KR 20200046061A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
solvate
compound
tautomer
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207008312A
Other languages
English (en)
Korean (ko)
Inventor
셰릴 에이 그라이스
올리비아 디 웨버
다니엘 제이 부자드
마이클 비 샤가피
토드 케이 존스
Original Assignee
룬드벡 라 졸라 리서치 센터 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 룬드벡 라 졸라 리서치 센터 인코포레이티드 filed Critical 룬드벡 라 졸라 리서치 센터 인코포레이티드
Publication of KR20200046061A publication Critical patent/KR20200046061A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020207008312A 2017-08-29 2018-08-28 스피로사이클 화합물 및 이를 제조하고 사용하는 방법 Ceased KR20200046061A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762551721P 2017-08-29 2017-08-29
US62/551,721 2017-08-29
PCT/US2018/048372 WO2019046318A1 (en) 2017-08-29 2018-08-28 SPIROCYCLIC COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF

Publications (1)

Publication Number Publication Date
KR20200046061A true KR20200046061A (ko) 2020-05-06

Family

ID=65527860

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207008312A Ceased KR20200046061A (ko) 2017-08-29 2018-08-28 스피로사이클 화합물 및 이를 제조하고 사용하는 방법

Country Status (27)

Country Link
US (1) US11142526B2 (enExample)
EP (1) EP3675847B1 (enExample)
JP (1) JP7257387B2 (enExample)
KR (1) KR20200046061A (enExample)
CN (1) CN111050765B (enExample)
AU (1) AU2018323459A1 (enExample)
BR (1) BR112020004101A2 (enExample)
CA (1) CA3072923A1 (enExample)
CL (1) CL2020000462A1 (enExample)
CO (1) CO2020001724A2 (enExample)
CR (1) CR20200089A (enExample)
DO (1) DOP2020000039A (enExample)
EA (1) EA202090312A1 (enExample)
EC (1) ECSP20013337A (enExample)
ES (1) ES2952332T3 (enExample)
GE (1) GEP20217327B (enExample)
IL (1) IL272580B (enExample)
JO (1) JOP20200023A1 (enExample)
MA (1) MA50041A (enExample)
MX (1) MX2020002251A (enExample)
NI (1) NI202000014A (enExample)
PE (1) PE20200664A1 (enExample)
PH (1) PH12020500372A1 (enExample)
SG (1) SG11202001022TA (enExample)
UA (1) UA126685C2 (enExample)
WO (1) WO2019046318A1 (enExample)
ZA (1) ZA202001208B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2800565T3 (pl) 2012-01-06 2020-09-21 Lundbeck La Jolla Research Center, Inc. Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci
KR20220034104A (ko) * 2019-07-09 2022-03-17 에프. 호프만-라 로슈 아게 신규 헤테로고리 화합물
CN116096723A (zh) * 2020-08-26 2023-05-09 豪夫迈·罗氏有限公司 用作magl抑制剂的杂环化合物
US11434222B2 (en) 2020-11-13 2022-09-06 H. Lundbeck A/S MAGL inhibitors
MX2024008337A (es) 2021-12-29 2024-07-30 Psy Therapeutics Inc Inhibicion de la monoacilglicerol lipasa (magl).
CN119137114A (zh) 2022-05-04 2024-12-13 H.隆德贝克有限公司 作为单酰基甘油脂肪酶抑制剂的(s)-1-(哒嗪-3-基氨基甲酰基)-6-氮杂螺[2.5]辛烷-6-甲酸1,1,1,3,3,3-六氟丙-2-酯的结晶形式
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008109A (es) 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
WO2008023720A1 (en) 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
CA2716863A1 (en) 2008-03-05 2009-09-11 Targacept, Inc. Sub-type selective amides of diazabicycloalkanes
FR2941696B1 (fr) 2009-02-05 2011-04-15 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
CA2775703C (en) 2009-09-29 2014-07-08 Polyone Corporation Polyester articles having simulated metallic or pearlescent appearance
KR101859409B1 (ko) 2009-10-23 2018-05-18 얀센 파마슈티카 엔.브이. 오렉신 수용체 조절제로서의 이치환된 옥타하이드로피롤로[3,4-c]피롤
WO2011109277A1 (en) 2010-03-04 2011-09-09 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
PL2800565T3 (pl) * 2012-01-06 2020-09-21 Lundbeck La Jolla Research Center, Inc. Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie
AU2013322838B2 (en) 2012-09-25 2018-02-01 F. Hoffmann-La Roche Ag New bicyclic derivatives
WO2015003002A1 (en) 2013-07-03 2015-01-08 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
US10093630B2 (en) * 2014-05-21 2018-10-09 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
MX2017011997A (es) 2015-03-18 2018-05-28 Abide Therapeutics Inc Carbamatos de piperacina y metodos de preparacion y uso.
PE20180694A1 (es) 2015-07-31 2018-04-23 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il-carbamato y derivados de 1,1,1-trifluoro-4-hidroxibutan-2-il-carbamato como inhibidores de magl
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
KR102388440B1 (ko) 2016-03-31 2022-04-19 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
ES2861648T3 (es) 2016-05-12 2021-10-06 Lundbeck La Jolla Research Center Inc Compuestos de espirociclo y procedimientos de fabricación y uso de los mismos
JOP20190049A1 (ar) 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
CA3043610A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Crystalline forms of a magl inhibitor
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
BR112019009992A2 (pt) 2016-11-16 2019-08-27 Abide Therapeutics Inc formulações farmacêuticas
CR20200088A (es) 2017-08-29 2020-04-08 Lundbeck La Jolla Research Center Inc Compuestos espirocíclicos y sus métodos de preparación y uso
MA50041A (fr) 2017-08-29 2020-07-08 Lundbeck La Jolla Research Center Inc Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci

Also Published As

Publication number Publication date
CA3072923A1 (en) 2019-03-07
EP3675847B1 (en) 2023-07-12
DOP2020000039A (es) 2020-08-31
MX2020002251A (es) 2020-07-20
NI202000014A (es) 2020-07-28
EP3675847A1 (en) 2020-07-08
IL272580B (en) 2022-09-01
PE20200664A1 (es) 2020-06-11
BR112020004101A2 (pt) 2020-09-24
UA126685C2 (uk) 2023-01-11
EP3675847C0 (en) 2023-07-12
US11142526B2 (en) 2021-10-12
GEP20217327B (en) 2021-12-10
IL272580A (en) 2020-03-31
EA202090312A1 (ru) 2020-08-05
ES2952332T3 (es) 2023-10-30
MA50041A (fr) 2020-07-08
ZA202001208B (en) 2021-08-25
JP7257387B2 (ja) 2023-04-13
JP2020532545A (ja) 2020-11-12
PH12020500372A1 (en) 2020-12-07
US20200255427A1 (en) 2020-08-13
EP3675847A4 (en) 2021-01-06
CO2020001724A2 (es) 2020-02-28
CN111050765B (zh) 2024-01-02
AU2018323459A1 (en) 2020-02-20
ECSP20013337A (es) 2020-04-22
WO2019046318A1 (en) 2019-03-07
RU2020107163A (ru) 2021-09-30
CR20200089A (es) 2020-04-08
JOP20200023A1 (ar) 2020-02-02
CN111050765A (zh) 2020-04-21
SG11202001022TA (en) 2020-03-30
CL2020000462A1 (es) 2020-07-10
RU2020107163A3 (enExample) 2022-03-15

Similar Documents

Publication Publication Date Title
JP7041198B2 (ja) Jak阻害剤である5-クロロ-2-ジフルオロメトキシフェニルピラゾロピリミジン化合物
JP7257387B2 (ja) スピロ環化合物並びにその作製及び使用方法
US11987584B2 (en) Heterobicyclic amides as inhibitors of CD38
KR102030609B1 (ko) Pi3k 억제제로서 헤테로시클릴아민
EP3077395B1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
JP7460264B2 (ja) ムスカリン性アセチルコリンm1受容体アンタゴニスト
JP2019535790A (ja) Gsk−3阻害剤
RU2781639C2 (ru) Спироциклические соединения и способы их получения и применения
HK40032869B (en) Spirocycle compounds and methods of making and using same
HK40032869A (en) Spirocycle compounds and methods of making and using same
EA041386B1 (ru) Спироциклические соединения и способы их получения и применения

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200320

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210826

Comment text: Request for Examination of Application

PN2301 Change of applicant

Patent event date: 20211013

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230904

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231115

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230904

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20230904

Comment text: Notification of reason for refusal

Patent event code: PE09021S01D